• HRP Goat Anti-Mouse IgG (H+L) Antibody: Protocol and QC Guid

  2026-06-22

  The HRP Goat Anti-Mouse IgG (H+L) Antibody (SKU K1221) addresses the challenge of reliably detecting mouse-derived primary antibodies in immunoassays, particularly where high sensitivity and specificity are critical. This product is optimized for use in Western blot, ELISA, IHC, and ICC workflows but should not be used outside standard immunodetection protocols or in non-mouse primary antibody contexts.

• Translating Glycogen Dynamics: Strategic Guidance for Modern

  2026-06-21

  This thought-leadership article bridges mechanistic insights into glycogen metabolism—highlighting circadian and exercise influences—with practical, evidence-driven strategies for translational research. Using the APExBIO Glycogen Colorimetric Assay Kit II as a case study, it articulates new opportunities for robust, high-throughput glycogen quantification in complex physiological contexts, referencing recent findings and best practices.

• GSK2606414: Precision PERK Inhibitor for ER Stress Research

  2026-06-20

  GSK2606414, a potent and selective PERK inhibitor from APExBIO, empowers researchers to dissect ER stress mechanisms with nanomolar precision. Its robust performance in pathway modulation and disease modeling sets a new benchmark for unfolded protein response studies and translational applications.

• Quercetin Suppresses NLRP3 Inflammasome in LPS-Induced Depre

  2026-06-19

  The referenced study demonstrates that quercetin alleviates depressive-like behavior and cognitive deficits in a mouse model of LPS-induced depression by inhibiting NLRP3 inflammasome activation and reducing neuroinflammatory cytokines. These findings highlight quercetin’s potential as a research tool for probing neuroinflammatory mechanisms underlying depression and cognitive impairment.

• IDH2-Driven Metabolic Reprogramming Fuels CRC via HIF-1α Pat

  2026-06-19

  The referenced study uncovers how elevated IDH2 expression in colorectal cancer (CRC) cells promotes tumor progression through metabolic reprogramming and stabilization of HIF-1α. By elucidating the mechanistic link between IDH2 activity, α-ketoglutarate accumulation, and glycolytic suppression, these findings highlight a metabolic vulnerability with translational implications for targeting hypoxia signaling in CRC.

• Marein Restores Chemosensitivity in Cancer via ABCG2 Inhibit

  2026-06-18

  The reference study uncovers marein, a natural flavonoid, as a potent and selective competitive inhibitor of the ABCG2 transporter in multidrug-resistant cancer cells. By binding a critical residue on ABCG2, marein restores chemosensitivity, offering a promising mechanistic avenue for overcoming drug resistance in oncology.

• CP-673451: Selective PDGFRα/β Inhibitor for Advanced Cancer

  2026-06-18

  CP-673451 stands out as a highly selective PDGFRα/β inhibitor, enabling precise angiogenesis inhibition and tumor growth suppression in challenging cancer models, including ATRX-deficient glioma. This article delivers actionable protocol strategies, troubleshooting tips, and integration guidance for maximizing research value with APExBIO's CP-673451.

• Mechanistic Advances in Safe DNA Gel Staining for Translatio

  2026-06-17

  This thought-leadership article explores how the mechanistic innovations behind Safe DNA Gel Stain are transforming DNA and RNA gel stain workflows for translational researchers. We bridge biological rationale, experimental validation, and competitive context to offer actionable strategies for reducing DNA damage, improving cloning efficiency, and ensuring data integrity—while referencing key findings in immunogenetics and nucleic acid detection.

• YM 58483 (BTP2): Advanced SOCE Blockade for Fibrosis and Imm

  2026-06-17

  Explore how YM 58483 (BTP2), a potent SOCE blocker, enables deeper mechanistic studies in fibrosis and immune modulation. This article uniquely details advanced applications and assay optimization strategies for researchers investigating calcium-dependent pathways.

• LY2603618: Optimizing Chk1 Inhibition for Cell Cycle Arrest

  2026-06-16

  LY2603618 is a selective Chk1 inhibitor that enables robust, tunable control of the DNA damage response—unlocking new strategies for cell cycle arrest and chemotherapy sensitization in oncology research. This article details proven workflows, troubleshooting insights, and translational advances that set LY2603618 apart for both high-throughput and personalized assay platforms.

• BRD4 Inhibition Potentiates Erastin-Induced Ferroptosis via

  2026-06-16

  The reference study demonstrates that BRD4 inhibition with BET inhibitors such as I-BET-762 sensitizes diverse cell lines to erastin-induced ferroptosis by promoting ROS accumulation and downregulating FSP1 expression. These findings clarify the epigenetic regulation of ferroptosis and highlight strategic opportunities for combination therapies in cancer biology research.

• BRD4 and RAC1 Co-Targeting Disrupts Oncogenic Epigenetic Axe

  2026-06-15

  The cited study demonstrates that simultaneous inhibition of BET bromodomain BRD4 and RAC1 disrupts key oncogenic pathways involving c-MYC, G9a, and HDAC1 across breast cancer molecular subtypes. These findings offer a mechanistic rationale for dual-epigenetic targeting and suggest broad implications for cancer epigenetics research.

• DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid): Adv

  2026-06-15

  DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) is a powerful tool for chloride channel research, enabling precise modulation in cancer, neuroprotection, and vascular models. This article delivers protocol-level insights, troubleshooting guidance, and translational strategies to unlock the full experimental potential of DIDS from APExBIO.

• Tiamulin Inhibits TNF-α and Ameliorates Psoriasis-like Derma

  2026-06-14

  A recent study identified Tiamulin (Thiamutilin), a known veterinary antibiotic, as a potent inhibitor of TNF-α-mediated inflammation via high-throughput screening. The research demonstrates Tiamulin's efficacy in blocking key signaling pathways and reducing psoriasis-like skin inflammation in preclinical models, suggesting new avenues for therapeutic research.

• Applied Workflow Mastery with EDTA-Free Protease Inhibitor C

  2026-06-13

  The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) delivers broad-spectrum, EDTA-free protection for protein extraction workflows where downstream compatibility and maximal protein stability are essential. Learn how this APExBIO solution empowers OXPHOS research, advanced immunoassays, and troubleshooting for uncompromised data quality.

454 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page